DekaBank Deutsche Girozentrale’s Fulcrum Therapeutics FULC Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,000	Closed	-$617K	–	1196
2025 Q4	$617K	Hold	60,000	–	–	﹤0.01%	964
2025 Q3	$611K	Hold	60,000	–	–	﹤0.01%	953
2025 Q2	$616K	Hold	60,000	–	–	﹤0.01%	946
2025 Q1	$568K	Hold	60,000	–	–	﹤0.01%	953
2024 Q4	$538K	Hold	60,000	–	–	﹤0.01%	990
2024 Q3	$568K	Hold	60,000	–	–	﹤0.01%	989
2024 Q2	$568K	Hold	60,000	–	–	﹤0.01%	984
2024 Q1	$568K	Hold	60,000	–	–	﹤0.01%	982
2023 Q4	$412K	Hold	60,000	–	–	﹤0.01%	1080
2023 Q3	$268K	Buy	+60,000	New	+$262K	﹤0.01%	1147

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

DekaBank Deutsche Girozentrale's FULC Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 60,000 shares — an estimated $617K sold.

DekaBank Deutsche Girozentrale first reported a position in FULC in Q3 2023 and held it in 10 quarters. The position peaked at $617K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 60,000 Fulcrum Therapeutics shares in Q1 2026, an estimated $617K.
DekaBank Deutsche Girozentrale first reported a position in Fulcrum Therapeutics in Q3 2023 and held it in 10 quarters.
DekaBank Deutsche Girozentrale's Fulcrum Therapeutics position peaked at $617K in Q4 2025.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.